Serum Sclerostin in Vascular Calcification in CKD: a Meta-analysis

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2023 Mar 7

PMID 36880646

Authors

Yan Lin

Liman Mao

Siqi Chen

Canxin Zhou

Affiliations

Soon will be listed here.

Abstract

Vascular calcification (VC) is recognized as a predictor of all-cause and CVD mortality in chronic kidney disease (CKD). VC in CKD is possibly associated with serum sclerostin. The study systematically investigated the role of serum sclerostin in VC in CKD. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, a systematic search was performed of the PubMed, Cochrane Library, and EMBASE databases from inception to 11 November 2022, to identify relevant eligible studies. The data were retrieved, analyzed, and summarized. The hazard ratios (HRs) and odds ratios (ORs) with their corresponding confidence intervals (CIs) were derived and pooled. Thirteen reports (3125 patients) met the inclusion criteria and were included. Sclerostin was associated with the presence of VC (pooled OR = 2.75, 95%CI = 1.81-4.19, < 0.01) and all-cause mortality (pooled HR = 1.22, 95%CI = 1.19-1.25, < 0.01) among patients with CKD, but with a decreased risk of cardiovascular events (HR = 0.98, 95%CI = 0.97-1.00, = 0.02). This meta-analysis suggests that serum sclerostin is associated with VC and all-cause mortality among patients with CKD.

References

Kanbay M, Siriopol D, Saglam M, Kurt Y, Gok M, Cetinkaya H . Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 2014; 99(10):E1854-61. DOI: 10.1210/jc.2014-2042. View

Qureshi A, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A . Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015; 88(6):1356-1364. DOI: 10.1038/ki.2015.194. View

Yang C, Chang Z, Chau Y, Chen A, Yang W, Yang A . Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant. 2015; 30(8):1356-63. DOI: 10.1093/ndt/gfv043. View

Vasiliadis E, Evangelopoulos D, Kaspiris A, Benetos I, Vlachos C, Pneumaticos S . The Role of Sclerostin in Bone Diseases. J Clin Med. 2022; 11(3). PMC: 8836457. DOI: 10.3390/jcm11030806. View

Kipourou K, ODriscoll J, Sharma R . Valvular Heart Disease in Patients with Chronic Kidney Disease. Eur Cardiol. 2022; 17:e02. PMC: 8819604. DOI: 10.15420/ecr.2021.25. View

Woldt E, Terrand J, Mlih M, Matz R, Bruban V, Coudane F . The nuclear hormone receptor PPARγ counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nat Commun. 2012; 3:1077. PMC: 3523725. DOI: 10.1038/ncomms2087. View

Hernandez P, Whitty C, Wardale R, Henson F . New insights into the location and form of sclerostin. Biochem Biophys Res Commun. 2014; 446(4):1108-13. DOI: 10.1016/j.bbrc.2014.03.079. View

Brandenburg V, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G . Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol. 2013; 14:219. PMC: 3851854. DOI: 10.1186/1471-2369-14-219. View

Nguyen A, Gomez D, Bell R, Campbell J, Clowes A, Gabbiani G . Smooth muscle cell plasticity: fact or fiction?. Circ Res. 2012; 112(1):17-22. PMC: 4135725. DOI: 10.1161/CIRCRESAHA.112.281048. View

10.

Lems W, Miceli-Richard C, Haschka J, Giusti A, Chistensen G, Kocijan R . Bone Involvement in Patients with Spondyloarthropathies. Calcif Tissue Int. 2022; 110(4):393-420. DOI: 10.1007/s00223-021-00933-1. View

11.

. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

12.

Couser W, Remuzzi G, Mendis S, Tonelli M . The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 80(12):1258-70. DOI: 10.1038/ki.2011.368. View

13.

Oluyombo R, Oguntade H, Soje M, Obajolowo O, Karim M . Obesity and CKD in Sub-Saharan Africa: A Narrative Review. Kidney Med. 2022; 4(2):100403. PMC: 8861962. DOI: 10.1016/j.xkme.2021.11.001. View

14.

Kirkpantur A, Balci M, Turkvatan A, Afsar B . Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia. 2015; 36(1):24-32. DOI: 10.1016/j.nefro.2015.07.006. View

15.

Sabbagh Y, Graciolli F, OBrien S, Tang W, Dos Reis L, Ryan S . Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27(8):1757-72. DOI: 10.1002/jbmr.1630. View

16.

London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18(9):1731-40. DOI: 10.1093/ndt/gfg414. View

17.

Pelletier S, Confavreux C, Haesebaert J, Guebre-Egziabher F, Bacchetta J, Carlier M . Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?. Osteoporos Int. 2015; 26(8):2165-74. DOI: 10.1007/s00198-015-3127-9. View

18.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

19.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

20.

Novo-Rodriguez C, Garcia-Fontana B, Luna-Del Castillo J, Andujar-Vera F, Avila-Rubio V, Garcia-Fontana C . Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS One. 2018; 13(6):e0199504. PMC: 6013204. DOI: 10.1371/journal.pone.0199504. View